VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer

Background: Neoadjuvant radiotherapy and chemotherapy, followed by surgical resection, are standard treatments for locally advanced rectal cancer (LARC). Emerging evidence has shown the efficacy of anti-programmed cell death protein 1 (anti-PD-1) therapy for patients with mismatch repair-deficient (...

ver descrição completa

Detalhes bibliográficos

Principais autores:	H. Bando, Y. Tsukada, S. Kumagai, Y. Miyashita, A. Taketomi, S. Yuki, Y. Komatsu, T. Akiyoshi, E. Shinozaki, Y. Kanemitsu, A. Takashima, M. Shiozawa, A. Shiomi, K. Yamazaki, N. Matsuhashi, H. Hasegawa, T. Kato, E. Oki, M. Fukui, M. Wakabayashi, N. Fuse, H. Nishikawa, M. Ito, T. Yoshino
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-03-01
coleção:	ESMO Gastrointestinal Oncology
Assuntos:	mismatch repair deficiency nivolumab locally advanced rectal cancer non-operative management whole-genome-based minimal residual disease testing whole-exome- and whole-transcriptome-based tumor immune microenvironment testing
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2949819823000468
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!